Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy.

Key facts

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Intervention

TQB2450 injection, docetaxel injection matching placebo, AL2846 capsules(drug)

Enrollment

518 enrolled

Eligibility

18-75 years · All sexes

Timeline

2023 – 2025

Study locations (30)

• The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
• Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing Municipality, China
• Peking University First Hospital, Beijing, Beijing Municipality, China
• Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing Municipality, China
• Beijing Tiantan Hospital Capital Medical University, Beijing, Beijing Municipality, China
• Chinese PLA General Hospital, Beijing, Beijing Municipality, China
• Beijing Cancer Hospital, Beijing, Beijing Municipality, China
• Beijing Chest Hospital Capital Medical University, Beijing, Beijing Municipality, China
• The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing Municipality, China
• Chongqing University Cancer Hospital, Chongqing, Chongqing Municipality, China
• Three Gorges Hospital Affiliated to Chongqing University, Chongqing, Chongqing Municipality, China
• Fujian Provincial Cancer Hospital, Fuzhou, Fujian, China
• The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
• Lanzhou University Second Hospital, Lanzhou, Gansu, China
• Gansu Provincial Cancer Hospital, Lanzhou, Gansu, China
• +15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Small cell lung cancer

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1, PHASE2NCT06694454
  Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
  National Cancer Institute (NCI)
• RECRUITINGNANCT07398599
  Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study
  Second Affiliated Hospital of Nanchang University
• RECRUITINGPHASE1, PHASE2NCT07480213
  Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
  Beijing Biotech
• RECRUITINGPHASE2NCT07329322
  Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
  Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
• RECRUITINGPHASE1, PHASE2NCT07227597
  A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
  Merck Sharp & Dohme LLC
• RECRUITINGPHASE1NCT07348211
  First in Human Study of SIM0610 in Solid Tumors
  Jiangsu Simcere Pharmaceutical Co., Ltd.
• RECRUITINGNANCT07161310
  Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint Inhibitors
  Goethe University
• RECRUITINGPHASE2NCT07304739
  Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases
  Tianjin Medical University Cancer Institute and Hospital

See all trials for Small cell lung cancer →